Abstract

Our understanding of isoform-specific activities of phosphatidylinositol 3-kinase (PI3K) is still rudimentary, and yet, deep knowledge of these non-redundant functions in the PI3K family is essential for effective and safe control of PI3K in disease. The two major isoforms of the regulatory subunits of PI3K are p85α and p85β, encoded by the genes PIK3R1 and PIK3R2, respectively. These isoforms show distinct functional differences that affect and control cellular PI3K activity and signaling [1–4]. In this study, we have further explored the differences between p85α and p85β by genetic truncations and substitutions. We have discovered unexpected activities of the mutant proteins that reflect regulatory functions of distinct p85 domains. These results can be summarized as follows: Deletion of the SH3 domain increases oncogenic and PI3K signaling activity. Deletion of the combined SH3-RhoGAP domains abolishes these activities. In p85β, deletion of the cSH2 domain reduces oncogenic and signaling activities. In p85α, such a deletion has an activating effect. The deletions of the combined cSH2 and iSH2 domains and also the deletion of the cSH2, iSH2 and nSH2 domains yield results that go in the same direction, generally activating in p85α and reducing activity in p85β. The contrasting functions of the cSH2 domains are verified by domain exchanges with the cSH2 domain of p85β exerting an activating effect and the cSH2 domain of p85α an inactivating effect, even in the heterologous isoform. In the cell systems studied, protein stability was not correlated with oncogenic and signaling activity. These observations significantly expand our knowledge of the isoform-specific activities of p85α and p85β and of the functional significance of specific domains for regulating the catalytic subunits of class IA PI3K.

Highlights

  • We recently reported an oncogenic activity of wild type p85β in cultures of avian embryonic fibroblasts [2]

  • Both consist of five structurally and functionally defined domains. They are, starting at the N-terminus: an SH3 domain, a RhoGAP domain ( referred to as breakpoint-cluster region homology (BH) domain that is flanked by two proline-rich regions), an N-terminal SH2 domain, an inter-SH2 region, and a C-terminal SH2 domain [1, 3]

  • We find that the SH3 domain exerts an inhibitory effect on oncogenic potential and PI 3-kinase signaling

Read more

Summary

Introduction

We recently reported an oncogenic activity of wild type p85β in cultures of avian embryonic fibroblasts [2]. This activity manifests itself in cellular transformation that alters cell morphology and increases the growth potential of the cells. It is correlated with enhanced PI3K signaling as documented by elevated phosphorylation of AKT at S473. The p85α and p85β proteins are encoded by two different genes, PIK3R1 and PIK3R2, but show extensive protein sequence homology. Both consist of five structurally and functionally defined domains. The most important interactions are an inhibitory binding of the nSH2 domain to the helical domain of the catalytic subunit p110 of PI3K and, for class IA PI3Ks, activating interactions of the SH2 domains with upstream signaling www.impactjournals.com/oncotarget proteins containing targeted phosphotyrosine residues [59]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call